ラクオリア創薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証GRT | 医薬品 | 4579/E25269 | RaQualia Pharma Inc. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2015/07/24 | 日証協 | 842,900株 | +20.92% | 234,100株 | +312.15% | 625,716株 | +9.31% | 126,200株 | +46.27% |
2015/07/17 | 日証協 | 697,100株 | -7.49% | 56,800株 | -70.01% | 572,416株 | -0.55% | 86,280株 | -25.26% |
2015/07/10 | 日証協 | 753,500株 | -6.63% | 189,400株 | -14.41% | 575,556株 | -28.69% | 115,440株 | -66.12% |
2015/07/03 | 日証協 | 807,000株 | +15.12% | 221,300株 | +143.72% | 807,166株 | +43.79% | 340,719株 | +193.22% |
2015/06/26 | 日証協 | 701,000株 | +4.43% | 90,800株 | +217.72% | 561,336株 | +2.94% | 116,200株 | +455.98% |
2015/06/19 | 日証協 | 671,279株 | -0.54% | 28,579株 | +1328.95% | 545,316株 | +1.9% | 20,900株 | +104.5% |
2015/06/12 | 日証協 | 674,900株 | -0.91% | 2,000株 | -95.48% | 535,136株 | +0.65% | 10,220株 | -34.65% |
2015/06/05 | 日証協 | 681,100株 | +2.04% | 44,200株 | +590.62% | 531,676株 | +4.29% | 15,640株 | -22.19% |
2015/05/29 | 日証協 | 667,500株 | 0% | 6,400株 | 0% | 509,816株 | 0% | 20,100株 | 0% |
2015/05/15 | 日証協 | 690,000株 | +1.43% | 3,200株 | -76.3% | 527,986株 | +1.05% | 5,930株 | -48.88% |
2015/05/08 | 日証協 | 680,300株 | -0.1% | 13,500株 | -32.5% | 522,486株 | +0.13% | 11,600株 | +39.26% |
2015/05/01 | 日証協 | 681,000株 | -1.26% | 20,000株 | +143.9% | 521,786株 | -0.62% | 8,330株 | +805.43% |
2015/04/24 | 日証協 | 689,700株 | -1.93% | 8,200株 | +331.58% | 525,036株 | -1.94% | 920株 | +2.22% |
2015/04/17 | 日証協 | 703,300株 | -1.88% | 1,900株 | -45.71% | 535,436株 | -1.09% | 900株 | -85.71% |
2015/04/10 | 日証協 | 716,800株 | +0.08% | 3,500株 | -94.68% | 541,336株 | -0.24% | 6,300株 | -69.71% |
2015/04/03 | 日証協 | 716,200株 | -10% | 65,800株 | +134.16% | 542,636株 | -7.59% | 20,800株 | -32.95% |
2015/03/20 | 日証協 | 773,100株 | +3.84% | 70,300株 | +266.15% | 577,416株 | -0.53% | 52,600株 | +248.34% |
2015/03/13 | 日証協 | 744,500株 | -0.45% | 19,200株 | -0.52% | 580,516株 | +0.33% | 15,100株 | +439.29% |
2015/03/06 | 日証協 | 747,900株 | -1.79% | 19,300株 | -73.04% | 578,616株 | -7.9% | 2,800株 | -87.1% |
※株式分割は考慮していませんのでご注意ください。
Page Top